Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310907 | 0.87 | TLR9 (0.42) | TLR9TLR8TLR7HCRTR2HCRTR1 | |
| SCHEMBL17310911 | 0.87 | TLR9 (0.42) | TLR9TLR8TLR7HCRTR2HCRTR1 | |
| SCHEMBL20101596 | 0.86 | CYP3A4 (0.48) | TP53ALDH1A1HSD17B10USP2 | |
| SCHEMBL16963441 | 0.84 | MEN1 (0.43) | ALDH1A1USP2ATXN2 | |
| SCHEMBL21323017 | 0.84 | MEN1 (0.43) | ALDH1A1USP2ATXN2 | |
| SCHEMBL16963443 | 0.84 | MEN1 (0.43) | ALDH1A1USP2ATXN2 | |
| SCHEMBL22910859 | 0.82 | ROCK2 (0.42) | TLR9TLR8TLR7 | |
| SCHEMBL16759723 | 0.82 | ROCK2 (0.42) | TLR9TLR8TLR7 | |
| SCHEMBL17310882 | 0.80 | HCRTR1 (0.40) | ALDH1A1HCRTR2HCRTR1ATXN2 | |
| SCHEMBL16963309 | 0.80 | RBP4 (0.42) | ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | TP53 1887/4885ALDH1A1 1038/4885HSD17B10 3122/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | TP53 1957/4885ALDH1A1 725/4885HSD17B10 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.